A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer

被引：24
|
作者：
Wainberg, Zev [1 ]
Hecht, J. Randolph [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, GI Oncol Program, Los Angeles, CA 90095 USA
来源：
CLINICAL COLORECTAL CANCER | 2006年 / 5卷 / 05期
关键词：
epidermal growth factor receptor; 5-fluorouracil; irinotecan; leucovorin; oxaliplatin; vascular endothelial growth factor;
D O I：
10.3816/CCC.2006.n.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：363 / 367
页数：5
相关论文
共 50 条
  • [31] Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
    Koeberle, D.
    Betticher, D. C.
    von Moos, R.
    Dietrich, D.
    Brauchli, P.
    Baertschi, D.
    Matter, K.
    Winterhalder, R.
    Borner, M.
    Anchisi, S.
    Moosmann, P.
    Kollar, A.
    Saletti, P.
    Roth, A.
    Frueh, M.
    Kueng, M.
    Popescu, R. A.
    Schacher, S.
    Hess, V.
    Herrmann, R.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (04) : 709 - 714
  • [32] Phase III results for first-line treatment for metastatic colorectal cancer
    Eleni Kotsiliti
    [J]. Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 65 - 65
  • [33] Phase III results for first-line treatment for metastatic colorectal cancer
    Kotsiliti, Eleni
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (02) : 65 - 65
  • [34] FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
    Modest, Dominik P.
    Martens, Uwe M.
    Riera-Knorrenschild, Jorge
    Greeve, Jobst
    Florschuetz, Axel
    Wessendorf, Swen
    Ettrich, Thomas
    Kanzler, Stephan
    Noerenberg, Dominik
    Ricke, Jens
    Seidensticker, Max
    Held, Swantje
    Buechner-Steudel, Petra
    Atzpodien, Jens
    Heinemann, Volker
    Seufferlein, Thomas
    Tannapfel, Andrea
    Reinacher-Schick, Anke C.
    Geissler, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (35) : 3401 - +
  • [35] Toripalimab combined with bevacizumab and chemotherapy as first-line treatment for refractory, recurrent or metastatic cervical cancer: a single-arm, open-label, phase II TRIA
    Li, Chen
    Peng, Peng
    Yao, Hairong
    Liu, Dantong
    He, Yonglan
    Liu, Shikai
    Cheng, Ninghai
    Cao, Dongyan
    Xiang, Yang
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A38 - A38
  • [36] Bevacizumab with chemotherapy for the first-line treatment of metastatic colorectal cancer: "NCI Slovakia" results
    Dolinsky, J.
    Salek, T.
    Hlavata, Z.
    Ivancova, H.
    Risnyovszka, Z.
    Mardiak, J.
    Koza, I
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
  • [37] Combination of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience
    Salek, T.
    Mego, M.
    Mardiak, J.
    Andrasina, I.
    Spanik, S.
    Malec, V.
    Barilla, R.
    Riedelova, K.
    Benedikty, A.
    Dammak, A.
    Porsok, S.
    Svabova, V.
    Chovanec, M.
    Cipkova, A.
    Usakova, V.
    Siskova, M.
    Jurisova, S.
    Dolinsky, J.
    Hlavata, Z.
    Andrezalova, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma
    Usakova, V.
    Sevcikova, K.
    Usak, J.
    Bartosova, Z.
    Mikulova, M.
    Spanik, S.
    [J]. NEOPLASMA, 2013, 60 (01) : 83 - 91
  • [39] FDA Review of a Panitumumab (Vectibix™) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer
    Giusti, Ruthann M.
    Cohen, Martin H.
    Keegan, Patricia
    Pazdur, Richard
    [J]. ONCOLOGIST, 2009, 14 (03): : 284 - 290
  • [40] Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
    Cunningham, David
    Lang, Istvan
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dongbok
    Jonker, Derek J.
    Osborne, Stuart
    Andre, Niko Alexander
    Waterkamp, Daniel
    Saunders, Mark P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345